Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412061 · ClinicalTrials.gov registry record · Phase 3
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
NCT00412061 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 429 participants.
The verdict
NCT00412061, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
Interventions
- DRUG Placebo
- DRUG Everolimus
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412061
The ClinicalTrials.gov registry entry for NCT00412061 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 429 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00412061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412061 about?
NCT00412061 is a clinical study titled "Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor". The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
What is the current status of trial NCT00412061?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2006-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00412061?
The interventions under investigation include: Placebo (DRUG), Everolimus (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT00412061?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.